| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| 500mg |
|
||
| 1g |
|
||
| Other Sizes |
|
Purity: ≥98%
SMI-16a (Pim1/2 Inhibitor IV) is a novel, potent, selective, cell-permeable, ATP-competitive Pim kinase inhibitor with IC50 values of 0.15, 0.02 and 48 μM for Pim1, Pim2 and PC3 cells, respectively. The Pim protein kinases are frequently overexpressed in prostate cancer and certain forms of leukemia and lymphoma. SMI-16a was identified by screening to be a Pim-1 inhibitor and was found to attenuate the autophosphorylation of tagged Pim-1 in intact cells. Although SMI-16a is a competitive inhibitor with respect to ATP, a screen of approximately 50 diverse protein kinases demonstrated that it has high selectivity for Pim kinases. SMI-16a demonstrated selectivities of more than 2500-fold and 400-fold for Pim-1 or Pim-2, respectively. Overall, SMI-16a has the potential to be developed into a novel anticancer agent.
| ln Vitro |
SMI-16a exhibits superior inhibitory properties against Pim-1 and Pim-2 [1]. In MM cells, treatment with Pim-2 short interfering RNA and the Pim inhibitor SMI-16a effectively restored osteoblastogenesis, which had been suppressed by all of the aforementioned inhibitors. Treatment with SMI-16a increases anabolic signaling mediated by BMP-2 and inhibits TGF-β signaling [2].
|
||
|---|---|---|---|
| ln Vivo |
SMI-16a was administered intraperitoneally to mice at a dose of 50 mg/kg every day for five days; a dose of 100 mg/kg was markedly hazardous. Five days a week of SMI-16a treatment decreased tumor growth in the mice by around 50% without resulting in weight loss. Red blood cell and white blood cell counts (including lymphocytes, monocytes, and granulocytes) were unaffected by subchronic treatment of SMI-16a, suggesting that the substance has no myelosuppressive effects. Because albumin, alkaline phosphatase, and alanine aminotransferase levels remain unchanged, SMI-16a is not hepatotoxic [1]. SMI-16a can successfully stop bone deterioration while preventing MM tumor growth in animal models of MM [2].
|
||
| Animal Protocol |
|
||
| References |
| Molecular Formula |
C13H13NO3S
|
|
|---|---|---|
| Molecular Weight |
263.31222
|
|
| Exact Mass |
263.061
|
|
| CAS # |
587852-28-6
|
|
| Related CAS # |
|
|
| PubChem CID |
6076476
|
|
| Appearance |
Light yellow to yellow solid powder
|
|
| LogP |
3.1
|
|
| Hydrogen Bond Donor Count |
1
|
|
| Hydrogen Bond Acceptor Count |
4
|
|
| Rotatable Bond Count |
4
|
|
| Heavy Atom Count |
18
|
|
| Complexity |
359
|
|
| Defined Atom Stereocenter Count |
0
|
|
| SMILES |
O=C(NC/1=O)SC1=C\C2=CC=C(OCCC)C=C2
|
|
| InChi Key |
GBWOSXZUTXXXQF-FLIBITNWSA-N
|
|
| InChi Code |
InChI=1S/C13H13NO3S/c1-2-7-17-10-5-3-9(4-6-10)8-11-12(15)14-13(16)18-11/h3-6,8H,2,7H2,1H3,(H,14,15,16)/b11-8-
|
|
| Chemical Name |
|
|
| Synonyms |
|
|
| HS Tariff Code |
2934.99.9001
|
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
|
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
|
|||
|---|---|---|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (9.49 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (9.49 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (9.49 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.7978 mL | 18.9890 mL | 37.9780 mL | |
| 5 mM | 0.7596 mL | 3.7978 mL | 7.5956 mL | |
| 10 mM | 0.3798 mL | 1.8989 mL | 3.7978 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Inhibition of Pim-1 in a cell-free kinase assay.
Inhibition of Pim-1 autophosphorylation in intact cells.
Antitumor activity of16a. |
Kinetics of inhibition of Pim-1 by4a.
Computational docking of4ato Pim-1.J Med Chem. 2009 Jan 8; 52(1): 74–86. |
Structures and potencies of reported Pim-1 inhibitors.J Med Chem. 2009 Jan 8; 52(1): 74–86. |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA
